DDInter1233 DDInter629
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Butoconazole
Butoconazole {u} (Compound) resembles {v} (Compound) Miconazole
Miconazole {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Mazindol
Mazindol {u} (Compound) resembles {v} (Compound) Haloperidol
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine (Compound) resembles Tolterodine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Mitotane (Compound) resembles Butoconazole (Compound) and Butoconazole (Compound) resembles Miconazole (Compound) and Miconazole may lead to a major life threatening interaction when taken with Eliglustat
Mitotane (Compound) resembles Mazindol (Compound) and Mazindol (Compound) resembles Haloperidol (Compound) and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Chlorpheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat